trial

Tocilizumab in Schizophrenia

NCTId NCT02874573
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Unknown
Enrollment 20 (estimated)
Sponsored by Brian Miller
Primary completion 2023-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Unknown
Enrollment
20 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2016-09
Primary completion
2023-12-31
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Tocilizumab

Sponsors

Brian MillerLead Sponsor
Brain & Behavior Research FoundationCollaborator

Investigators

1
Brian Miller, MD, PhD, MPHPrincipal Investigator

Sites

1 total
Augusta, United States

Facts & assertions

4 sourced
Enrollment
20
Phase
PHASE1
Primary Completion Date
2023-12-31
Status
UNKNOWN
relationships
The graph out of here
drug
Tocilizumab
drug
lead_sponsor
Brian Miller
company
collaborator
Brain & Behavior Research Foundation
company
indication
Psychotic Disorders
indication
Psychotic Disorders
indication
Schizophrenia
indication
investigator
Brian Miller, MD, PhD, MPH
person